Published On: Jan 02, 2018
The U.S. and China market for asthma and COPS drugs is anticipated to showcase a steep trajectory for growth in the coming years. According to a report by Transparency Market Research (TMR), the leading companies in the U.S. and China asthma and COPD drugs market accounted for just under 64.0% in 2015, demonstrating the consolidated nature of this industry, along with high levels of competition among the established players. Merck & Co. Inc., Novartis AG, Astrazeneca plc, GlaxoSmithKline plc and Boehringer Ingelheim are currently among the leading names in the market.
According to the report, the market is slated to ascend from a valuation of US$13.0 bn in 2015 to be worth US$18.7 bn by the end of 2024. On the off chance that these numbers remain constant, the market is expected to exhibit a healthy 4.1% CAGR over the forecast period.
Combination Drugs Segment to Emerge as Leading Segment Due to High Demand
Based on the different classes of drugs in the U.S. & China, the report bifurcates the future extent of development for assortments, for instance anti-inflammatory drugs, bronchodilators, combination drugs and monoclonal antibodies.
Of these, the fragment of combination drugs is directly the leading market segment in the coming years. It represented a 54% of the U.S. and China asthma and COPD drugs market in 2015 and is relied upon to keep on dominating all through forecast duration. Combination drugs advantage from the suggestions from organizations such as the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and Global Initiative for Asthma (GINA), which see blend sedates as the more secure course of overseeing asthma and COPD. The rise of new medication applicants in this section will reinforce its development potential in the market over the years to come.
Govt Support to Offer Lucrative Market Opportunity
Asthma and COPD are two maladies encountering expanding pervasiveness comprehensively because of a mix of variables, including the maturing populace and the rising contamination levels, especially in rising nations. COPD is one of the best five reasons for inability and demise in industrialized nations and the fourth-driving reason for deaths over the world. The utilization of medications has risen as a successful answer for the treatment of COPD and asthma, which will lead to high market opportunity. The market is driven by the developing patient COPD and asthmatic populace, and also FDA endorsements for the novel items and its wide acknowledgment among the patient populace. Expanding government activities to control COPD and asthma additionally fuel the development for this market. Increment in presentation of non-specific medications, and rising predominance of asthma combined with geriatric populace and lifestyle changes are the main considerations that credit to the ascent in growth of this market.
The data and information presented in this review are based on a TMR report titled as “Asthma and COPD Drugs Market (Drug Class - Bronchodilators, Anti-inflammatory Drugs, Monoclonal Antibodies, and Combination Drugs; Indication - Asthma and COPD) - U.S. and China Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024”
U.S. and China Asthma and COPD Drugs Market, by Drug Class
- Short Acting Beta-2 Agonists
- Long Acting Beta-2 Agonists
- Anti-cholinergic Agents
- Anti-inflammatory Drugs
- Oral and Inhaled Corticosteroids
- Phosphodiesterase Type-4 Inhibitors
- Monoclonal Antibodies
- Combination Drugs
U.S. and China Asthma and COPD Drugs Market, by Indication
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact